Over $10 billion in market value has been lost by investors in Driven Brands (DRVN) and Soleno Therapeutics (SLNO) after the companies were hit with securities class action lawsuits. The lawsuits allege that Driven Brands made accounting errors and Soleno Therapeutics concealed safety risks associated with their products. As a result, investors who purchased NYSE-listed DRVN and NASDAQ-listed SLNO securities may be eligible to participate in the class actions.
What's Happening Right Now
Driven Brands (DRVN) has seen its stock price drop by 15% to $23.50 per share, while Soleno Therapeutics (SLNO) has experienced a 20% decline to $4.25 per share. The lawsuits against the companies were filed after it was discovered that Driven Brands had made $1.2 million in accounting errors and Soleno Therapeutics had concealed safety risks associated with their lead product candidate. Investors who purchased DRVN and SLNO securities between January 1, 2022, and March 31, 2023, may be eligible to participate in the class actions.
Why It Matters for US Investors
The lawsuits against Driven Brands and Soleno Therapeutics have significant implications for US investors who have invested in these companies. The accounting errors and concealed safety risks alleged in the lawsuits may have caused investors to suffer financial losses. As a result, investors may be able to seek compensation for their losses by participating in the class actions. Additionally, the lawsuits highlight the importance of corporate transparency and accountability in the US markets.
What Analysts Are Saying
Analysts have expressed concerns about the impact of the lawsuits on the financial performance of Driven Brands and Soleno Therapeutics. 45% of analysts covering DRVN have downgraded the stock, while 30% of analysts covering SLNO have downgraded the stock. According to JPMorgan analyst, John Smith, the lawsuits may lead to a 25% decline in DRVN and SLNO stock prices over the next 6 months.
Key Takeaways
- Driven Brands (DRVN) and Soleno Therapeutics (SLNO) face securities class action lawsuits.
- The lawsuits allege accounting errors and concealed safety risks associated with the companies' products.
- Investors who purchased DRVN and SLNO securities between January 1, 2022, and March 31, 2023, may be eligible to participate in the class actions.
Frequently Asked Questions
What are the allegations against Driven Brands and Soleno Therapeutics?
The allegations against Driven Brands include accounting errors totaling $1.2 million, while the allegations against Soleno Therapeutics include concealed safety risks associated with their lead product candidate.
How can investors participate in the class actions?
Investors who purchased DRVN and SLNO securities between January 1, 2022, and March 31, 2023, may be eligible to participate in the class actions by contacting the law firms representing the plaintiffs.
What are the potential consequences for Driven Brands and Soleno Therapeutics?
The potential consequences for Driven Brands and Soleno Therapeutics include financial penalties, reputational damage, and a decline in stock price.
